BGB 290

Drug Profile

BGB 290

Alternative Names: BeiGene-290; BGB-290; PARP-Tankyrase programme - BeiGene; PARPi - BeiGene

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator BeiGene
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Tankyrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer; Solid tumours

Most Recent Events

  • 21 Dec 2016 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (PO)
  • 18 Aug 2016 The China Food and Drug Administration approves Clinical Trial application for BGB 290 in Cancer
  • 18 Aug 2016 US FDA approves IND application for BGB 290 in Cancer before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top